+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Pulmonary Arterial Hypertension Market by Drug Class, Route Of Administration, Distribution, End User - Global Forecast to 2030- Product Image
Pulmonary Arterial Hypertension Market by Drug Class, Route Of Administration, Distribution, End User - Global Forecast to 2030- Product Image
Sale

Pulmonary Arterial Hypertension Market by Drug Class, Route Of Administration, Distribution, End User - Global Forecast to 2030

  • PDF Icon

    Report

  • 194 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5011141
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Pulmonary Arterial Hypertension Market is undergoing significant transformation, presenting key opportunities and challenges for senior decision-makers. Evolving therapeutic strategies, global policy shifts, and advanced technologies continue to redefine market dynamics, requiring expert navigation for sustained growth and competitiveness.

Market Snapshot: Pulmonary Arterial Hypertension Market

The Pulmonary Arterial Hypertension Market grew from USD 9.12 billion in 2024 to USD 9.77 billion in 2025. It is expected to continue growing at a CAGR of 7.46%, reaching USD 14.04 billion by 2030. This steady expansion reflects the introduction of novel therapies and innovative care models, aligning with rising patient volumes and stakeholder investments across key regions.

Scope & Segmentation

This report delivers a comprehensive analysis across the competitive, clinical, and regulatory spectrum. Senior leaders gain actionable market intelligence through segmentation by product class, treatment approach, channel distribution, and region.

  • Drug Class: Endothelin receptor antagonists, phosphodiesterase-5 inhibitors, and prostanoids offer a diverse landscape for competitive and clinical differentiation.
  • Route of Administration: Therapy regimens analyzed include oral, intravenous, and subcutaneous formulations, reflecting evolving patient management preferences and care settings.
  • Distribution Channels: Market access is evaluated through hospital pharmacies, retail pharmacies, and online pharmacies, each with unique opportunities for patient engagement and service delivery.
  • End User: The report examines adoption by academic and research institutions, clinics, and hospitals, revealing the influence of each on innovation and patient outcomes.
  • Regional Coverage: Comprehensive geographic examination includes Americas (United States, Canada, Mexico, Brazil, Argentina), EMEA (multiple European, Middle Eastern, and African countries), and Asia-Pacific (China, India, Japan, Australia, and others), recognizing local reimbursement, regulatory, and market access complexities.
  • Company Developments: In-depth analysis of recent activities from major pharmaceutical players, including pipeline expansion, collaborations, and digital health integration initiatives.

Pulmonary Arterial Hypertension Market: Key Takeaways

  • Therapeutic innovation is expanding, with a shift toward multi-mechanism combination therapies and precision approaches that address the multifactorial nature of pulmonary arterial hypertension.
  • Digital health adoption—such as remote patient monitoring and telemedicine integration—enables real-time care adjustments and patient-centric support, becoming a core differentiator for leading organizations.
  • Market entry and expansion strategies increasingly hinge on demonstrating real-world outcomes, evidence-based value, and patient adherence improvements to satisfy payer and provider requirements.
  • Supply chain and sourcing resilience are top priorities, driven by policy and regulatory shifts impacting the cost and availability of pharmaceutical components.
  • Collaboration among pharmaceutical leaders, technology partners, and research institutions accelerates innovation and drives forward adaptive clinical development and commercialization pathways.

Tariff Impact: Navigating Regulatory Change

The introduction of new U.S. tariffs in 2025 directly influences cost structures across the pulmonary arterial hypertension supply chain. Pharmaceutical manufacturers, distributors, and healthcare providers must reassess sourcing strategies, production capabilities, and contract structures to mitigate margin pressures. These policy shifts compel proactive sensitivity analyses and enhanced cross-stakeholder coordination to preserve therapy access and address evolving reimbursement expectations.

Methodology & Data Sources

Findings in this report are derived from a robust blend of secondary and primary research. Rigorous reviews of regulatory filings, clinical literature, and company disclosures form the foundation, complemented by interviews with key opinion leaders in clinical practice, academia, and payer organizations. Comprehensive data triangulation and stakeholder validation ensure reliability and deepen market insight.

Why This Report Matters

  • Senior decision-makers receive a concise roadmap for aligning growth strategies with dynamism in therapy innovation, reimbursement, and policy change.
  • Cohesive segmentation and regional analysis empower targeted investment, resource optimization, and accelerated market access.
  • Strategic intelligence highlights competitive positioning and partnership models that maximize long-term business value.

Conclusion

This report equips stakeholders with critical clarity to navigate and capitalize on the evolving Pulmonary Arterial Hypertension Market. By addressing therapeutic, operational, and policy complexities, it supports confident, data-driven decisions at every leadership level.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Pulmonary Arterial Hypertension Market, by Drug Class
8.1. Introduction
8.2. Endothelin Receptor Antagonists
8.3. Phosphodiesterase-5 Inhibitors
8.4. Prostanoids
9. Pulmonary Arterial Hypertension Market, by Route Of Administration
9.1. Introduction
9.2. Intravenous
9.3. Oral
9.4. Subcutaneous
10. Pulmonary Arterial Hypertension Market, by Distribution
10.1. Introduction
10.2. Hospital Pharmacy
10.3. Online Pharmacy
10.4. Retail Pharmacy
11. Pulmonary Arterial Hypertension Market, by End User
11.1. Introduction
11.2. Academic & Research Institutions
11.3. Clinics
11.4. Hospitals
12. Americas Pulmonary Arterial Hypertension Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Pulmonary Arterial Hypertension Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Pulmonary Arterial Hypertension Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Alembic Pharmaceuticals Limited
15.3.2. AstraZeneca PLC
15.3.3. Aurobindo Pharma Limited
15.3.4. Bayer AG
15.3.5. Boehringer Ingelheim GmbH
15.3.6. Cipla Limited
15.3.7. CMP Pharma, Inc.
15.3.8. Dr. Reddy’s Laboratories Limited
15.3.9. Eli Lilly and Company
15.3.10. Gilead Sciences, Inc.
15.3.11. GlaxoSmithKline PLC
15.3.12. Gossamer Bio, Inc.
15.3.13. Gyre Therapeutics, Inc.
15.3.14. Hikma Pharmaceuticals PLC
15.3.15. Johnson & Johnson Services, Inc.
15.3.16. Lupin Limited
15.3.17. Merck KGaA
15.3.18. Novartis AG
15.3.19. Pfizer, Inc.
15.3.20. Sun Pharmaceutical Industries Limited
15.3.21. Teva Pharmaceutical Industries Ltd.
15.3.22. Torrent Pharmaceuticals Limited
15.3.23. United Therapeutics Corporation
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. PULMONARY ARTERIAL HYPERTENSION MARKET MULTI-CURRENCY
FIGURE 2. PULMONARY ARTERIAL HYPERTENSION MARKET MULTI-LANGUAGE
FIGURE 3. PULMONARY ARTERIAL HYPERTENSION MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. PULMONARY ARTERIAL HYPERTENSION MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. PULMONARY ARTERIAL HYPERTENSION MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. PULMONARY ARTERIAL HYPERTENSION MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ENDOTHELIN RECEPTOR ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PHOSPHODIESTERASE-5 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PROSTANOIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. AMERICAS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 23. AMERICAS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 24. AMERICAS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 25. AMERICAS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 26. AMERICAS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 27. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 28. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 29. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 30. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 31. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 32. CANADA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 33. CANADA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 34. CANADA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 35. CANADA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 36. MEXICO PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 37. MEXICO PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 38. MEXICO PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 39. MEXICO PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 40. BRAZIL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 41. BRAZIL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 42. BRAZIL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 43. BRAZIL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 44. ARGENTINA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 45. ARGENTINA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 46. ARGENTINA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 47. ARGENTINA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 48. EUROPE, MIDDLE EAST & AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 49. EUROPE, MIDDLE EAST & AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 50. EUROPE, MIDDLE EAST & AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 51. EUROPE, MIDDLE EAST & AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 52. EUROPE, MIDDLE EAST & AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 53. UNITED KINGDOM PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 54. UNITED KINGDOM PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 55. UNITED KINGDOM PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 56. UNITED KINGDOM PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 57. GERMANY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 58. GERMANY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 59. GERMANY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 60. GERMANY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 61. FRANCE PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 62. FRANCE PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 63. FRANCE PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 64. FRANCE PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 65. RUSSIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 66. RUSSIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 67. RUSSIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 68. RUSSIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 69. ITALY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 70. ITALY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 71. ITALY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 72. ITALY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 73. SPAIN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 74. SPAIN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 75. SPAIN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 76. SPAIN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 77. UNITED ARAB EMIRATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 78. UNITED ARAB EMIRATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 79. UNITED ARAB EMIRATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 80. UNITED ARAB EMIRATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 81. SAUDI ARABIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 82. SAUDI ARABIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 83. SAUDI ARABIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 84. SAUDI ARABIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 85. SOUTH AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 86. SOUTH AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 87. SOUTH AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 88. SOUTH AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 89. DENMARK PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 90. DENMARK PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 91. DENMARK PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 92. DENMARK PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 93. NETHERLANDS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 94. NETHERLANDS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 95. NETHERLANDS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 96. NETHERLANDS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 97. QATAR PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 98. QATAR PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 99. QATAR PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 100. QATAR PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 101. FINLAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 102. FINLAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 103. FINLAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 104. FINLAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 105. SWEDEN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 106. SWEDEN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 107. SWEDEN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 108. SWEDEN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 109. NIGERIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 110. NIGERIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 111. NIGERIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 112. NIGERIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 113. EGYPT PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 114. EGYPT PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 115. EGYPT PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 116. EGYPT PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 117. TURKEY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 118. TURKEY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 119. TURKEY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 120. TURKEY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 121. ISRAEL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 122. ISRAEL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 123. ISRAEL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 124. ISRAEL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 125. NORWAY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 126. NORWAY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 127. NORWAY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 128. NORWAY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 129. POLAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 130. POLAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 131. POLAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 132. POLAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 133. SWITZERLAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 134. SWITZERLAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 135. SWITZERLAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 136. SWITZERLAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 137. ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 138. ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 139. ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 140. ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 141. ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 142. CHINA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 143. CHINA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 144. CHINA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 145. CHINA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 146. INDIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 147. INDIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 148. INDIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 149. INDIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 150. JAPAN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 151. JAPAN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 152. JAPAN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 153. JAPAN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 154. AUSTRALIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 155. AUSTRALIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 156. AUSTRALIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 157. AUSTRALIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 158. SOUTH KOREA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 159. SOUTH KOREA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 160. SOUTH KOREA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 161. SOUTH KOREA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 162. INDONESIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 163. INDONESIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 164. INDONESIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 165. INDONESIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 166. THAILAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 167. THAILAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 168. THAILAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 169. THAILAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 170. PHILIPPINES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 171. PHILIPPINES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 172. PHILIPPINES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 173. PHILIPPINES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 174. MALAYSIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 175. MALAYSIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 176. MALAYSIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 177. MALAYSIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 178. SINGAPORE PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 179. SINGAPORE PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 180. SINGAPORE PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 181. SINGAPORE PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 182. VIETNAM PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 183. VIETNAM PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 184. VIETNAM PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 185. VIETNAM PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 186. TAIWAN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 187. TAIWAN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 188. TAIWAN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 189. TAIWAN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 190. PULMONARY ARTERIAL HYPERTENSION MARKET SHARE, BY KEY PLAYER, 2024
TABLE 191. PULMONARY ARTERIAL HYPERTENSION MARKET, FPNV POSITIONING MATRIX, 2024

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Pulmonary Arterial Hypertension market report include:
  • Alembic Pharmaceuticals Limited
  • AstraZeneca PLC
  • Aurobindo Pharma Limited
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Cipla Limited
  • CMP Pharma, Inc.
  • Dr. Reddy’s Laboratories Limited
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Gossamer Bio, Inc.
  • Gyre Therapeutics, Inc.
  • Hikma Pharmaceuticals PLC
  • Johnson & Johnson Services, Inc.
  • Lupin Limited
  • Merck KGaA
  • Novartis AG
  • Pfizer, Inc.
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Limited
  • United Therapeutics Corporation

Table Information

Report AttributeDetails
No. of Pages194
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 9.77 Billion
Forecasted Market Value ( USD ) by 2030 $ 14.04 Billion
Compound Annual Growth Rate7.4%
Regions CoveredGlobal
No. of Companies Mentioned24

Related Topics

Related Reports

Pulmonary Arterial Hypertension Market Report 2025 - Product Image

Pulmonary Arterial Hypertension Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Pulmonary Arterial Hypertension (PAH) Drugs Market 2024-2028 - Product Image

Pulmonary Arterial Hypertension (PAH) Drugs Market 2024-2028

  • Report
  • 180 Pages
  • Global
From
Pulmonary Hypertension - Pipeline Insight, 2025 - Product Image

Pulmonary Hypertension - Pipeline Insight, 2025

  • Clinical Trials
  • 240 Pages
  • Global
From
2024 Global Forecast for Pulmonary Arterial Hypertension Market (2025-2030 Outlook)-High Tech & Emerging Markets Report - Product Image

2024 Global Forecast for Pulmonary Arterial Hypertension Market (2025-2030 Outlook)-High Tech & Emerging Markets Report

  • Report
  • 132 Pages
  • Global
From
Chronic Thromboembolic Pulmonary Hypertension - Pipeline Insight, 2025 - Product Image

Chronic Thromboembolic Pulmonary Hypertension - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From

About the Pulmonary Arterial Hypertension Drug Market

Pulmonary Arterial Hypertension (PAH) is a rare, progressive, and life-threatening form of high blood pressure that affects the arteries in the lungs and the right side of the heart. It is a type of cardiovascular disease, and is treated with a variety of drugs. These drugs are used to reduce symptoms, improve exercise capacity, and slow the progression of the disease. Commonly used drugs include prostacyclin analogues, endothelin receptor antagonists, phosphodiesterase-5 inhibitors, and soluble guanylate cyclase stimulators. The PAH drug market is a rapidly growing segment of the cardiovascular drug market. It is driven by the increasing prevalence of PAH, the development of new drugs, and the increasing awareness of the disease. The market is expected to continue to grow in the coming years, as new drugs are developed and approved. Some of the major companies in the PAH drug market include Actelion Pharmaceuticals, Gilead Sciences, GlaxoSmithKline, Novartis, Pfizer, and United Therapeutics. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.